Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.

about

Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.

Item

http://www.wikidata.org/entity/Q52919426

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Cyclophosphamide plus granuloc ...... atients with multiple myeloma.

@en

Cyclophosphamide plus granuloc ...... atients with multiple myeloma.

@nl

type

Item

label

Cyclophosphamide plus granuloc ...... atients with multiple myeloma.

@en

Cyclophosphamide plus granuloc ...... atients with multiple myeloma.

@nl

prefLabel

Cyclophosphamide plus granuloc ...... atients with multiple myeloma.

@en

Cyclophosphamide plus granuloc ...... atients with multiple myeloma.

@nl

P1476

Cyclophosphamide plus granuloc ...... atients with multiple myeloma.

@en

P2093

Hung Chang

http://www.w3.org/2001/XMLSchema#string

Ming-Chung Kuo

http://www.w3.org/2001/XMLSchema#string

Po-Nan Wang

http://www.w3.org/2001/XMLSchema#string

Tung-Liang Lin

http://www.w3.org/2001/XMLSchema#string

Tzung-Chih Tang

http://www.w3.org/2001/XMLSchema#string

Yu-Hsing Hung

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.

Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma.

Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.

P304

423-428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCA.21421

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26340986

http://www.w3.org/2001/XMLSchema#string